153 related articles for article (PubMed ID: 24943391)
1. Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism.
Bousman CA; Sarris J; Won ES; Chang HS; Singh A; Lee HY; Ham BJ; Tan CH; Lee MS; Ng CH
J Clin Psychopharmacol; 2014 Oct; 34(5):645-8. PubMed ID: 24943391
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.
Ng C; Sarris J; Singh A; Bousman C; Byron K; Peh LH; Smith DJ; Tan CH; Schweitzer I
Hum Psychopharmacol; 2013 Sep; 28(5):516-22. PubMed ID: 24014145
[TBL] [Abstract][Full Text] [Related]
3. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder.
Won ES; Chang HS; Lee HY; Ham BJ; Lee MS
Neuropsychobiology; 2012; 66(4):221-9. PubMed ID: 23095326
[TBL] [Abstract][Full Text] [Related]
4. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK
JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806
[TBL] [Abstract][Full Text] [Related]
5. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH
Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812
[TBL] [Abstract][Full Text] [Related]
6. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.
Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt DJ; Metspalu A
Eur Neuropsychopharmacol; 2009 Jun; 19(6):451-6. PubMed ID: 19272758
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy.
Porcelli S; Fabbri C; Serretti A
Eur Neuropsychopharmacol; 2012 Apr; 22(4):239-58. PubMed ID: 22137564
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment.
Su YA; Li JT; Dai WJ; Liao XM; Dong LC; Lu TL; Bousman C; Si TM
Int Clin Psychopharmacol; 2016 May; 31(3):127-33. PubMed ID: 26745768
[TBL] [Abstract][Full Text] [Related]
9. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study.
Arias B; Catalán R; Gastó C; Gutiérrez B; Fañanás L
J Clin Psychopharmacol; 2003 Dec; 23(6):563-7. PubMed ID: 14624186
[TBL] [Abstract][Full Text] [Related]
10. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence.
Muhonen LH; Lahti J; Alho H; Lönnqvist J; Haukka J; Saarikoski ST
Psychiatry Res; 2011 Mar; 186(1):53-7. PubMed ID: 20800901
[TBL] [Abstract][Full Text] [Related]
11. Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population.
Mandal T; Bairy LK; Sharma PSVN
Eur J Clin Pharmacol; 2020 Jun; 76(6):807-814. PubMed ID: 32253447
[TBL] [Abstract][Full Text] [Related]
12. Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response.
Domschke K; Tidow N; Schwarte K; Deckert J; Lesch KP; Arolt V; Zwanzger P; Baune BT
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1167-76. PubMed ID: 24679990
[TBL] [Abstract][Full Text] [Related]
13. Serotonin transporter genotype and function in relation to antidepressant response in Koreans.
Myung W; Lim SW; Kim S; Kim H; Chung JW; Seo MY; Kim JW; Carroll BJ; Kim DK
Psychopharmacology (Berl); 2013 Jan; 225(2):283-90. PubMed ID: 22885912
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
[TBL] [Abstract][Full Text] [Related]
15. Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression.
Poland RE; Lesser IM; Wan YJ; Gertsik L; Yao J; Raffel LJ; Lin KM; Myers HF
Life Sci; 2013 May; 92(20-21):967-70. PubMed ID: 23562852
[TBL] [Abstract][Full Text] [Related]
16. Amygdala responses to quetiapine XR and citalopram treatment in major depression: the role of 5-HTTLPR-S/Lg polymorphisms.
Ramasubbu R; Burgess A; Gaxiola-Valdez I; Cortese F; Clark D; Kemp A; Goodyear B; Macqueen G; Bech-Hansen NT; Foster J; Diwadkar VA
Hum Psychopharmacol; 2016 Mar; 31(2):144-55. PubMed ID: 26879101
[TBL] [Abstract][Full Text] [Related]
17. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders.
Kronenberg S; Apter A; Brent D; Schirman S; Melhem N; Pick N; Gothelf D; Carmel M; Frisch A; Weizman A
J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):741-50. PubMed ID: 18315446
[TBL] [Abstract][Full Text] [Related]
18. SLC6A4 variation and citalopram response.
Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
[TBL] [Abstract][Full Text] [Related]
19. Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.
Manoharan A; Shewade DG; Rajkumar RP; Adithan S
Eur J Clin Pharmacol; 2016 Oct; 72(10):1215-1220. PubMed ID: 27439447
[TBL] [Abstract][Full Text] [Related]
20. SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.
Shiroma PR; Drews MS; Geske JR; Mrazek DA
Am J Geriatr Psychiatry; 2014 Nov; 22(11):1140-8. PubMed ID: 23973251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
